[go: up one dir, main page]

WO2008091681A3 - Theramutein modulators - Google Patents

Theramutein modulators Download PDF

Info

Publication number
WO2008091681A3
WO2008091681A3 PCT/US2008/000960 US2008000960W WO2008091681A3 WO 2008091681 A3 WO2008091681 A3 WO 2008091681A3 US 2008000960 W US2008000960 W US 2008000960W WO 2008091681 A3 WO2008091681 A3 WO 2008091681A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
activators
inhibitors
endogenous protein
endogenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/000960
Other languages
French (fr)
Other versions
WO2008091681A2 (en
Inventor
Gerard M Housey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2008091681A2 publication Critical patent/WO2008091681A2/en
Publication of WO2008091681A3 publication Critical patent/WO2008091681A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.
PCT/US2008/000960 2007-01-23 2008-01-23 Theramutein modulators Ceased WO2008091681A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89728207P 2007-01-23 2007-01-23
US60/897,282 2007-01-23

Publications (2)

Publication Number Publication Date
WO2008091681A2 WO2008091681A2 (en) 2008-07-31
WO2008091681A3 true WO2008091681A3 (en) 2008-09-25

Family

ID=39645081

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/000960 Ceased WO2008091681A2 (en) 2007-01-23 2008-01-23 Theramutein modulators

Country Status (1)

Country Link
WO (1) WO2008091681A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102060782A (en) * 2010-11-18 2011-05-18 孙智华 Method for preparing chloropyrimidines or analogues thereof
GB201300435D0 (en) 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
JP6291031B2 (en) 2013-04-05 2018-03-14 ザ プロクター アンド ギャンブル カンパニー Personal care composition containing pre-emulsified formulation
US10806688B2 (en) 2014-10-03 2020-10-20 The Procter And Gamble Company Method of achieving improved volume and combability using an anti-dandruff personal care composition comprising a pre-emulsified formulation
US9993404B2 (en) 2015-01-15 2018-06-12 The Procter & Gamble Company Translucent hair conditioning composition
CA2977961A1 (en) 2015-02-25 2016-09-01 The Procter & Gamble Company Fibrous structures comprising a surface softening composition
WO2016196514A1 (en) * 2015-06-01 2016-12-08 Regents Of The University Of Minnesota Thiourea catalysts
JP6866343B2 (en) 2015-07-10 2021-04-28 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ Fabric care composition containing metathesis-unsaturated polyol ester
CN108472223A (en) 2016-01-20 2018-08-31 宝洁公司 Hair conditioning composition comprising monoalkyl glyceryl ether
JP6864379B2 (en) 2016-03-31 2021-04-28 オンターナル セラピューティック インコーポレイテッドＯｎｃｔｅｒｎａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Indole analogues and their use
US10894932B2 (en) 2016-08-18 2021-01-19 The Procter & Gamble Company Fabric care composition comprising glyceride copolymers
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
CN118748993A (en) 2021-12-28 2024-10-08 日本新药株式会社 Indazole compounds and drugs
AU2023275780A1 (en) 2022-05-25 2024-12-05 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
CN119823036B (en) * 2025-01-07 2025-10-10 北京师范大学 HYNIC modified 4- (2-aminoethyl) benzenesulfonamide derivative and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115992A1 (en) * 2004-05-23 2005-12-08 Housey Pharmaceuticals, Inc. Theramutein modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115992A1 (en) * 2004-05-23 2005-12-08 Housey Pharmaceuticals, Inc. Theramutein modulators

Also Published As

Publication number Publication date
WO2008091681A2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
WO2008091681A3 (en) Theramutein modulators
WO2007037898A3 (en) Theramutein modulators
WO2009053484A3 (en) Electron deficient olefins and curable compositions prepared therefrom
WO2011106629A3 (en) Modified proteins and methods of making and using same
MX2010010209A (en) Substituted 4-hydroxypyrimidine-5-carboxamides.
AU2009236219A8 (en) Silencing of CSN5 gene expression using interfering RNA
EA201001860A1 (en) DPP-4 inhibitors for the treatment of non-alcoholic fatty liver
WO2009037473A3 (en) Nucleobase characterisation
EA201100300A1 (en) COMPOSITIONS AND METHODS INTENDED FOR THE DIRECTED IMPACT OF ANTIBODIES ON C5 COMPLEMENT SYSTEM
WO2009126623A3 (en) Expression of heterologous sequences
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
WO2010053573A3 (en) Screen for inhibitors of filovirus and uses therefor
WO2009002440A3 (en) Compositions comprising human egfr-sirna and methods of use
WO2008157697A3 (en) Copolymer assay
WO2008118626A3 (en) Inhibitors of jnk and methods for identifying inhibitors of jnk
WO2007016591A3 (en) Compositions and methods for monitoring and altering protein folding and solubility
GEP20125586B (en) Novel method for synthesis of (7-methoxy-l-naphthyl)-acetonitrile and application thereof in synthesis of agomelatine
MX2009012170A (en) Weak acid based concrete stain.
EP2447252A3 (en) Theramutein modulators
EP3341112A4 (en) METHODS AND COMPOSITIONS FOR PROTEIN PURIFICATION AND REACTION OF AN ENZYME
WO2011100752A3 (en) Methods and materials for assessing rna expression
WO2010000851A3 (en) Methods for modulating angiogenesis via dystrophin dp71
WO2009137291A3 (en) Spiroazaindoles
WO2010042685A3 (en) Inhibitors of the atb(0,+) transporter and uses thereof
WO2009090269A8 (en) Markers and diagnostic methods for metastasis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08713273

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08713273

Country of ref document: EP

Kind code of ref document: A2